KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Raw Materials data on record, last reported at $82.8 million in Q4 2025.

  • For Q4 2025, Raw Materials rose 18.7% year-over-year to $82.8 million; the TTM value through Dec 2025 reached $82.8 million, up 18.7%, while the annual FY2025 figure was $82.8 million, 18.7% up from the prior year.
  • Raw Materials reached $82.8 million in Q4 2025 per ACAD's latest filing, up from $77.8 million in the prior quarter.
  • Across five years, Raw Materials topped out at $83.7 million in Q2 2025 and bottomed at $1.5 million in Q2 2021.
  • Average Raw Materials over 5 years is $32.4 million, with a median of $11.5 million recorded in 2023.
  • Peak YoY movement for Raw Materials: tumbled 43.83% in 2021, then soared 934.36% in 2024.
  • A 5-year view of Raw Materials shows it stood at $6.2 million in 2021, then dropped by 16.25% to $5.2 million in 2022, then skyrocketed by 501.34% to $31.3 million in 2023, then surged by 122.73% to $69.7 million in 2024, then rose by 18.7% to $82.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $82.8 million in Q4 2025, $77.8 million in Q3 2025, and $83.7 million in Q2 2025.